Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694241 | 1.00 | ALDH1A1 (0.57) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL6690737 | 1.00 | ALDH1A1 (0.57) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL6693207 | 0.90 | POLB (0.57) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL6691284 | 0.88 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL30342198 | 0.88 | TP53 (0.52) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL29005218 | 0.88 | TP53 (0.52) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL25583422 | 0.87 | KDM4E (0.58) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL2982891 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL6694388 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 | |
| SCHEMBL17992279 | 0.85 | LMNA (0.51) | ALDH1A1HSD17B10KDM4EL3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-7034187-B2 | Poly(aralkyl ketone)s and methods of preparing the same | AGENCY FOR SCIENCE, TECHNOLOGY, AND RESEARCH (SG) | 2006-04-25 | — | — | US | disclosed |
| US-20050272905-A1 | NOVEL POLY(ARALKYL KETONE)S AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2005-12-08 | — | — | US | disclosed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5463063-A | Preparation of thalidomide; inhibitor of tumor necrosis factor | CELGENE CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272905-A1 | NOVEL POLY(ARALKYL KETONE)S AND METHODS OF PREPARING THE SAME | ADSL, KHK, PKLR | ALDH1A1 1700/4885HSD17B10 954/4885KDM4E 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.